Analysts Set Bicycle Therapeutics Limited (NASDAQ:BCYC) PT at $24.80

Dovie Salais

Bicycle Therapeutics Limited (NASDAQ:BCYC) has been given a consensus recommendation of “Buy” by the eight analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. […]

Bicycle Therapeutics Limited (NASDAQ:BCYC) has been given a consensus recommendation of “Buy” by the eight analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $24.80.

A number of analysts recently issued reports on BCYC shares. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, August 6th. Zacks Investment Research lowered Bicycle Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. BidaskClub upgraded Bicycle Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Canaccord Genuity upped their target price on Bicycle Therapeutics from $23.50 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Oppenheimer restated a “buy” rating and issued a $27.00 target price on shares of Bicycle Therapeutics in a research note on Tuesday, September 22nd.

Hedge funds have recently modified their holdings of the stock. FMR LLC purchased a new stake in Bicycle Therapeutics during the 2nd quarter valued at about $3,277,000. Morgan Stanley lifted its holdings in Bicycle Therapeutics by 32,450.0% in the 1st quarter. Morgan Stanley now owns 3,255 shares of the company’s stock worth $44,000 after buying an additional 3,245 shares during the period. Squarepoint Ops LLC purchased a new stake in Bicycle Therapeutics in the 1st quarter worth approximately $179,000. UBS Group AG purchased a new stake in Bicycle Therapeutics in the 2nd quarter worth approximately $36,000. Finally, Advisor Group Holdings Inc. lifted its holdings in Bicycle Therapeutics by 34,000.0% in the 2nd quarter. Advisor Group Holdings Inc. now owns 34,100 shares of the company’s stock worth $537,000 after buying an additional 34,000 shares during the period. Institutional investors own 35.54% of the company’s stock.

NASDAQ:BCYC opened at $18.51 on Thursday. Bicycle Therapeutics has a 52-week low of $7.50 and a 52-week high of $21.59. The firm has a market cap of $327.63 million, a price-to-earnings ratio of -8.90 and a beta of -0.42. The business’s fifty day moving average is $18.98 and its 200 day moving average is $16.92.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.19). Bicycle Therapeutics had a negative net margin of 434.29% and a negative return on equity of 43.74%. The company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $2.11 million. On average, sell-side analysts predict that Bicycle Therapeutics will post -2.49 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Recommended Story: How to use beta for portfolio diversification

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bicycle Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source Article

Next Post

How to sell your car to a private party

AUTOTRADER © istock Selling your car privately requires a bit more effort than simply trading it in at a dealership, but it can be worth it. Unlike a trade-in, where a dealer must factor in costs of reconditioning, marketing, and reselling your vehicle, a private sale goes to the end […]

Subscribe US Now